Quality control and GMP synthesis of68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer

Quality control and GMP synthesis of68Ga-prostate-specific membrane antigen-11 for detection of low- and high-grade prostate cancer

Prostate-specific membrane antigen (PSMA) labeled with68Ga routinely used with higher sensibility and specificity than other radiotracers for detection of low and high grades of prostate cancer using positron emission tomography (PET)-computed tomography.68Ge/68Ga generators are generally used with...

Full description

Bibliographic Details
Main Authors:	Majid Assadi, Habibollah Dadgar
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2020-01-01
Series:	World Journal of Nuclear Medicine
Subjects:	computed tomography positron emission tomography prostate cancer prostate-specific membrane antigen-11 quality control
Online Access:	http://www.wjnm.org/article.asp?issn=1450-1147;year=2020;volume=19;issue=2;spage=93;epage=98;aulast=Assadi

Similar Items

68 Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for prostate cancer imaging: A narrative literature review
by: Jose M Oliveira, et al.
Published: (2017-01-01)

External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
by: Henk B. Luiting, et al.
Published: (2021-06-01)

Gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography compared with diagnostic computed tomography in relapsed prostate cancer
by: Marcus Edward Asokendaran, et al.
Published: (2019-01-01)

Oligometastasis to testis in prostate cancer: Role of gallium-68 prostate-specific membrane antigen positron-emission tomography computed tomography
by: Manoj Gupta, et al.
Published: (2021-01-01)

Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer
by: Timothy N. Kwan, et al.
Published: (2021-06-01)

Epididymal metastasis from prostate adenocarcinoma: An unusual and challenging diagnosis suspected in gallium-68 prostate-specific membrane antigen-positron emission tomography/computed tomography and histologically confirmed
by: Sofia Santos-Lopes, et al.
Published: (2017-01-01)

Initial experience of Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography imaging in evaluation of biochemical recurrence in prostate cancer patients
by: Aravintho Natarajan, et al.
Published: (2019-01-01)

Prostate cancer nodal oligometastasis accurately assessed using prostate-specific membrane antigen positron emission tomography-computed tomography and confirmed histologically following robotic-assisted lymph node dissection
by: Dermot B O′Kane, et al.
Published: (2016-01-01)

Restaging the Biochemical Recurrence of Prostate Cancer with [<sup>68</sup>Ga]Ga-PSMA-11 PET/CT: Diagnostic Performance and Impact on Patient Disease Management
by: Aloÿse Fourquet, et al.
Published: (2021-03-01)

Intense fluoro-2-deoxyglucose uptake in high-grade prostatic adenocarcinoma with negligible prostate-specific membrane antigen expression
by: Tansel Cakir, et al.
Published: (2019-01-01)

68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends
by: Cristian Udovicich, et al.
Published: (2017-12-01)

False-positive prostate cancer bone metastases on magnetic resonance imaging correctly classified on gallium-68-prostate-specific membrane antigen positron emission tomography computed tomography
by: Sofiullah Olayinka Abubakar, et al.
Published: (2018-01-01)

Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and Its Role in Salvage Lymph Node Dissection
by: Marieke J. Krimphove, et al.
Published: (2020-01-01)

Incremental value of 68-gallium-prostate-specific membrane antigen positron emission tomography/computed tomography in patients with abnormal prostate-specific antigen and benign transrectal ultrasound biopsy
by: Manoj Gupta, et al.
Published: (2018-01-01)

[<sup>68</sup>Ga]Ga-PSMA-11: The First FDA-Approved <sup>68</sup>Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
by: Ute Hennrich, et al.
Published: (2021-07-01)

Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
by: Sangwon Han, et al.
Published: (2021-04-01)

Value of 11C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases
by: Shuoming Zhou, et al.
Published: (2021-02-01)

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis
by: Sungmin Woo, et al.
Published: (2020-09-01)

Impact of 68GA-PSMA PET / CT on treatment of patients with recurrent / metastatic high risk prostate cancer - a multicenter study
by: Aline B. Mattiolli, et al.

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
by: Panagiotis J. Vlachostergios, et al.
Published: (2021-02-01)

Prostate-specific antigen and prostate-specific antigen kinetics in predicting 18F-sodium fluoride positron emission tomography-computed tomography positivity for first bone metastases in patients with biochemical recurrence after radical prostatectomy
by: James Yoon, et al.
Published: (2017-01-01)

Uptake of prostate-specific membrane antigen-targeted18F-DCFPyL in avascular necrosis of the femoral head
by: Gonzalo Torga, et al.
Published: (2019-01-01)

Updates of prostate cancer staging: Prostate-specific membrane antigen
by: Niranjan J Sathianathen, et al.
Published: (2016-12-01)

Nuclear medicine in prostate cancer: A new era for radiotracers
by: Vincenzo Cuccurullo, et al.
Published: (2018-01-01)

Application Progress of 68Ga-PSMA PET/CT in Recurrent Prostate Cancer
by: YANG Liping, et al.
Published: (2018-07-01)

Prostate-specific antigen cutoff value for ordering sodium fluoride positron emission tomography/computed tomography bone scan in patients with prostate cancer
by: Ismet Sarikaya, et al.
Published: (2018-01-01)

68Ga-PSMA PET/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy
by: Yuigi Yuminaga, et al.
Published: (2021-04-01)

18F-prostate-specific membrane antigen positron emission tomography computed tomography incidental finding in a patient after COVID-19 infection
by: Siroos Mirzaei, et al.
Published: (2020-01-01)

Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography
by: Theodoros Tsakiridis, et al.
Published: (2020-01-01)

Dynamic 11C-Choline PET / CT for the primary diagnosis of prostate cancer
by: Shay Golan, et al.

Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions
by: Sebastian Meißner, et al.
Published: (2017-10-01)

A case of hepatic focal nodular hyperplasia mimicking hepatocellular carcinoma identified on gallium-68-prostate-specific membrane antigen positron emission tomography/computed tomography
by: Seckin Bilgic, et al.
Published: (2021-01-01)

A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: An initial experience
by: Manoj Gupta, et al.
Published: (2017-01-01)

Can gallium-68 prostate-specific membrane antigen ligand be a potential radiotracer for renal cortical positron emission tomography imaging?
by: Ismet Sarikaya, et al.
Published: (2018-01-01)

Comparison of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography for Primary Staging of Prostate Cancer: A Systematic Review and Meta-analysis
by: Sui Wai Ling, et al.
Published: (2021-11-01)

The Role of 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Preoperative Lymph Node Staging in Intermediate/High Risk Patients With Prostate Cancer: A Diagnostic Meta-Analysis
by: Xiang Tu, et al.
Published: (2020-08-01)

Is there the role of 18F-choline PET/CT in prostate cancer patients?
by: Hodolič Marina
Published: (2012-01-01)

11C-Choline-Avid but 18F-FDG-Nonavid Prostate Cancer with Lymph Node Metastases on Positron Emission Tomography
by: Kazuhiro Kitajima, et al.
Published: (2016-11-01)

Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern
by: Yafu Yin, et al.
Published: (2019-01-01)

Novel imaging in prostate cancer
by: Orestis Porfyris, et al.
Published: (2020-01-01)